Hepatitis B virus (HBV) infection is a global. Chronic Hepatitis B Infection in Adolescents Who Received Primary Infantile Vaccination
|
|
- Scarlett Lucas
- 5 years ago
- Views:
Transcription
1 Chronic Hepatitis B Infection in Adolescents Who Received Primary Infantile Vaccination Tzu-Wei Wu, 1 * Hans Hsienhong Lin, 2,3 * and Li-Yu Wang 1,4 Hepatitis B virus (HBV) infection is a global health issue. Universal infantile hepatitis B (HB) vaccination is very efficacious. However, HBV infections among those immunized subjects have been reported. The long-term efficacy of postnatal passive-active HB vaccination in high-risk subjects is not well explored. A total of 8,733 senior high school students who were born after July 1987 were assayed for hepatitis B surface antigen (HBsAg) and antibodies to HBsAg (anti-hbs). The overall HBsAg and anti-hbs-positive rates were 1.9% and 48.3%, respectively. The HBsAg-positive rate was 15% in HB immunoglobulin (HBIG) recipients (adjusted odds ratio [OR]: 15.63; 95% confidence interval [CI]: ). Among students who did not receive HBIG, there was a significantly negative association between HB vaccination dosage and HBsAg-positive rate (P for trend ). Adjusted ORs for those who received 4, 3, and 1 to 2 doses were 1.00, 1.52 (95% CI: ), and 2.85 (95% CI: ), respectively. Among HBIG recipients, the HBsAgpositive rate was significantly higher in subjects with maternal hepatitis B e antigen (HBeAg) positivity and who received HBIG off-schedule. A booster dose of HB vaccination was administered to 1974 HBsAg- and anti-hbs-negative subjects. Prebooster and a postbooster blood samples were drawn for anti-hbs quantification. The proportions of postbooster anti-hbs titer <10 miu/ml was 27.9%. Subjects with prebooster anti-hbs titers of miu/ml had significantly higher postbooster anti-hbs titers than those with prebooster anti-hbs titers of <1.0 miu/ml (P < ). Conclusion: Having maternal HBeAg positivity is the most important determinant for HBsAg positivity in adolescents who received postnatal passive-active HB vaccination 15 years before. A significant proportion of complete vaccinees may have lost their immunological memories against HBsAg. (HEPATOLOGY 2013;57:38-45) Hepatitis B virus (HBV) infection is a global issue, affecting two billion people in the world, with 360 million chronic carriers of hepatitis B surface antigen (HBsAg). 1 The sequalae of chronic HBV infection, including hepatic failure, liver cirrhosis, and hepatocellular carcinoma, shorten lives and impose great economic burdens on society. Taiwan has been an endemic area of HBV infection, with an HBV infection rate of 95% and a 15%-20% HBsAg carrier rate in the general population. 2 Vertical transmission is the main cause of persistent HBV infection in Taiwan 3 ; fortunately, it can be blocked by passive-active vaccination after birth. 4-6 To control HBV infection, a hepatitis B (HB) vaccination program was launched in Taiwan in 1984, starting with newborns of highly infectious mothers, and expanded to all newborns in The remarkable effectiveness of universal infantile HB vaccination program (UIHBVP) is well documented In Taiwan, the HBV infection and carrier rates of children born after the program has declined dramatically The incidence of infantile fulminant hepatitis 13 and childhood hepatocellular carcinoma has also declined. 14,15 However, the efficacy of the postnatal passive-active HB vaccination is not 100%. HBV chronic infections Abbreviations: anti-hbc, antibodies to hepatitis B core antigen; anti-hbs, antibodies to hepatitis B surface antigen; HB, hepatitis B; HBeAg, hepatitis B e antigen; HBIG, hepatitis B immunoglobulin; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus. From the 1 Department of Medicine, Mackay Medical College, New Taipei City, Taiwan; 2 Department of Gastroenterology, Tzu Chi General Hospital, Taipei Branch, New Taipei City, Taiwan; 3 Department of Internal Medicine, School of Medicine, Tzu Chi University, Hualien, Taiwan; 4 Department of Public Health, Taipei Medical University, Taipei City, Taiwan. Received April 25, 2012; accepted July 17, Supported by grants from the National Science Council, Taiwan (NSC B MY3), and grants from Mackay Medical College, Taiwan (981B03, 991A01). *These authors contributed equally to this work. 38
2 HEPATOLOGY, Vol. 57, No. 1, 2013 WU, LIN, AND WANG 39 in immunized infants and children has been reported in Taiwan and other countries Immunoprophylaxis failure occurred in a few high-risk infants even though HB immunoglobulin (HBIG) was administered immediately after delivery. 4,17,18,22,23 The HBsAg-positive rates in high-risk infants age 0.5 to 2 years were 2%-9% after postnatal passive-active HB vaccination Several studies have shown that the protective effects of HB vaccination can last for at least 10 years However, the long-term protective effects of HB vaccination in high-risk subjects are not well explored. Additionally, it seems that the risks of HBV infection are increased dramatically during adolescence. The cumulative 10-year risk of HBV infection in postnatal passiveactive HB vaccinated subjects was less than 15%. 24,25 On the contrary, more than 30% of these high-risk subjects were anti-hbc positive at 15 years of age. 26 Here we report our recent study on HBV chronic infection among senior high school students who were born after the implementation of UIHBVP. We found that more than 15% of vaccinated students born to highly infectious mothers became HBsAg carriers. We also found that approximately one-sixth of complete vaccinees may have no or low immunological memories against HBsAg. Subjects and Methods Universal Infantile HB Vaccination Program (UIHBVP). In July 1984, the Government of Taiwan initiated an HB mass vaccination program aiming primarily at interrupting mother-to-infant vertical transmission. High-risk infants were inoculated freely with a single dose of 145 IU of HBIG (Abbott Laboratories, Cutter, or Green Cross, Taiwan) within 24 hours after delivery. A 5 lg dose of a plasma-derived HBV vaccine (HavacB; Pasteur-Merieux, Lyon, France, or its equivalent derivative, Lifeguard hepatitis B vaccine, Hsin-Chu, Taiwan) was given to the infants at the first week of age. Two additional doses of HB vaccine were given at ages of 5 and 9 weeks. A booster dose of HB vaccination was given at 12 months of age. 7 Recombinant HB vaccine was not available in Taiwan until July After 1 November 1992, the plasmaderived vaccine was replaced by recombinant yeast vaccines H-B-Vax II (Merck Sharp & Dohame, Rahway, NJ) and Engerix-B (SmithKline Beecham, Rixensart, Belgium). 10 In July 1986, this program was extended to all neonates, then to preschool children in July 1987, to primary-school children in 1988, to middle-school children in 1989, and to adults in Since 1991, the vaccination log-sheet of first grade children were checked and unvaccinated or incompletely vaccinated children were given catch-up HB vaccination. 10 Study Area. Hualien County is located in east Taiwan. It has an area of 4,629 km 2 and a population of 336,733 citizens in January Approximately 90% of the land area of Hualien County consists of mountains, in which the Central Mountain Chain are in the west and the East Coast Mountains are in the east. The population density for Hualien County and the whole Taiwan area is 72.8 and persons per km 2, respectively. 29 Hualien has one city and nine rural and three mountainous townships. Fifty-six percent of the total population of Hualien County reside in Hualien City and Jian Township, both of which are located in northern Hualien. The prevalence rate of HBsAg in subjects born before 1978 was 17.0%, 11 which was similar to that of the whole islands. 2 There are seven public and six private senior high schools in Hualien County and the total number of freshmen is 4,000 annually. Study Subjects. There were two parts to the present study, including HBV seroepidemiology and HB revaccination study. The procedures of study subject recruitment of the seroepidemiological study were similar to our previous study. 12 In brief, an invitation letter coupled with a short questionnaire and informed consent form was delivered to 10,648 freshmen of seven public senior high schools during October 2003 to May Consenting students were asked to provide their vaccination record and assayed for serum HBsAg and antibodies to HBsAg (anti-hbs). Students with seronegativity for both anti-hbs and HBsAg were further invited to participate in the HB revaccination study. The study protocols were similar to our previous study, with little modification. 30 In brief, a booster dose of 20 lg HB vaccine (Engerix-B, GlaxoSmithKline Biologicals, Rixensart, Belgium) was administered to each participant. One prebooster and Address reprint requests to: Dr. Li-Yu Wang, Department of Medicine, Mackay Medical College, No. 46, Sec. 3, Jhong-Jheng Rd., San-Jhih District, New Taipei City, Taiwan. yannbo@mmc.edu.tw; fax: Copyright VC 2012 by the American Association for the Study of Liver Diseases. View this article online at wileyonlinelibrary.com. DOI /hep Potential conflict of interest: Nothing to report.
3 40 WU, LIN, AND WANG HEPATOLOGY, January 2013 one postbooster blood sample was obtained at the date and 4 to 6 weeks after the booster dose for anti-hbs quantification. All students were tested for serum antibody against HBV core antigen (anti-hbc). The study protocols were approved by the Institutional Review Board of Tzu Chi Medical Center and Taipei Medical University. Records of Primary Infantile HB Vaccination. Since 1983, the Department of Health of Taiwan implemented vaccination registration. A yellow vaccination log-sheet was provided to each woman who gave birth recently. The health institutions were obligated to register the dates and associated information on the yellow log-sheet. In the study, consenting students were asked to provide a copy of their vaccination record. To increase the completeness of the vaccination data, we also reviewed and abstracted HB vaccination records from 13 local health stations and major healthcare institutions in Hualien County. For those who had two sources of HB vaccination data, the copies that were provided by the study subjects were used as the primary source. Records of maternal HBeAg status for HBIG recipients were also reviewed and abstracted. Definitions of Attributes of and Responses to HB Vaccination. All the study subjects were born between July 1987 and July During this period, only highrisk infants who were born to mothers with HBeAg positivity or reciprocal serum titers of HBsAg higher than 2,560 were administered a single dose of HBIG and the recommended dates of HB vaccination were the 1st, 5th, and 9th weeks after delivery. 30 In the present study, infantile and early childhood HB vaccination was defined as those administered before the age of 3 years. Completion of HB vaccination was defined as subjects who received at least 3 doses of HB vaccine before 12 months of age. On-schedule HB vaccination was defined as follows: (1) the first dose was administered at the first week after delivery; (2) the second dose was administered at 4 to 6 weeks of age; and (3) the third dose was administered at 8 to 10 weeks of age. The response rate to a booster dose of HB vaccine was defined as the proportion of booster recipients whose postbooster titer was 10 miu/ml. 30,31 The overall anti-hbs seropositive rate, designated as PR T, after a booster dose of HB vaccine was approximated by the following formula: PR T ¼ PR 1 þð1 PR 1 ÞPR 2 Where PR 1 is the anti-hbs seropositive rate before booster and PR 2 is the response rate in the booster recipients. Serologic Testing. HBsAg and anti-hbs serostatus in blood samples obtained for the seroepidemiological study were detected by microparticle enzyme immunoassays (MEIA) with commercial kits AxSYN HBsAg (V2) (Abbott Diagnostics, North Chicago, IL) and anti-hbs (Abbott Diagnostics), respectively. Anti-HBc serostatus was also detected by MEIA with the commercial kit AxSYN CORE (Abbott Diagnostics). Serum anti-hbs titers in pre- and postbooster blood samples were assayed by a quantitative method with the commercial kit AxSYN AUSAB (Abbott Diagnostics). The detection limit of this quantitative method was 1.0 miu/ml. Statistical Analysis. Pearson s chi 2 test and Fisher s exact test were used to assess whether significant differences exist in the positive rate of HBsAg among students with different attributes. P 0.05 or less was regarded as statistically significant. Multivariate logistic regression models were used to estimate the adjusted odds ratio (aor) and the 95% confidence interval (95% CI) of being HBsAg-positive for potential determinants. Results A total of 8,813 (83%) freshmen were recruited. Eighty students who were born before July 1987 or did not have blood drawn were excluded, leaving a total of 8,733 individuals in the seroepidemiological study. The mean age with standard deviation at enrollment was 15.6 (0.4) years; 52.8% were male. The seropositive rate of HBsAg and anti-hbs were 1.9% and 48.3%, respectively. Histories of infantile HB vaccination were not available for 819 (9.4%) subjects. Approximately 87% of subjects had official documentation of receiving 3 doses of HB vaccination before 3 years of age. Three hundred and eighty-one (4.8%) subjects had documented HBIG injection. Records of maternal HBeAg status of HBIG recipients were left blank in 211 (55.4%) subjects. Among 7,914 subjects who had official documentation of HB vaccination, 6,804 of them had data from two different sources. The consistency in the dates of HB vaccination was 94.5%. To assess the effects of HB vaccination on HBV chronic infection, we restricted analyses to 7,914 subjects who had official documentation of HB vaccination. Table 1 shows that there was a significantly negative association between HB vaccination dosage and HBsAg-positive rate (P for trend ¼ ). As compared with those who received four doses of HB vaccination, adjusted ORs of HBsAg positivity were
4 HEPATOLOGY, Vol. 57, No. 1, 2013 WU, LIN, AND WANG 41 Table 1. HBsAg-Positive Rates in 7,914 Adolescents with Documentation of HB Vaccination Histories HBsAgþ Crude OR Adjusted OR Total n (%) OR 95% CI aor* 95% CI HB vaccination during infancy and early childhood Dosage 4 doses 6, (1.8) doses 1, (2.3) 1.29 ( ) 1.40 ( ) 12 doses (2.8) 1.64 ( ) 2.38 ( ) Completion Yes 6, (1.9) No (2.0) 1.09 ( ) 1.29 ( ) On-schedule Yes 3, (2.0) No 4, (1.8) 0.89 ( ) 1.05 ( ) HBIG injection ND 7, (1.2) Yes (15.4) ( ) ( ) *In addition to histories of HB vaccination, ORs were also adjusted for age and gender. Defined as HB vaccination administered before 3 years of age. Defined as those who received 3 doses of HB vaccination before 12 months of age. 0-7 days, 4-6 weeks, and 8-10 weeks after birth for the 1 st,2 nd, and 3 rd dose, respectively. k test for trend, P ¼ ; P < OR, adjusted odds ratio; CI, confidence interval; HB, hepatitis B; HBIG, hepatitis B immunoglobulin; HBsAg, hepatitis B surface antigen; ND, no documentation (95% CI: ) and 2.38 (95% CI: ) for those who received 3 and 1 to 2 doses, respectively. The HBsAg-positive rate was significantly higher in HBIG recipients than that of subjects without HBIG injection (1.3% versus 15.4%; adjusted OR ¼ 15.63, ). Table 2 shows that among 7,537 students who did not receive HBIG, there was a significantly negative association between HB vaccination dosage and HBsAg positive rate (P for trend ¼ 0.011). As compared with those who received four doses of HB vaccination, the adjusted ORs were 1.52 (95% CI: ) and 2.85 (95% CI: ) for those who received 3 and 1 to 2 doses, respectively. Among 377 HBIG recipients, no significant association was observed. Table 3 shows the HBsAg-positive rates and timing of HBIG injection and maternal HBeAg serostatus among 373 passive-active HB vaccination recipients. The HBsAg-positive rates were nonsignificantly lower Table 2. HBsAg Chronic Infection and HB Vaccination Histories in 7,914 with Documentation of HB Vaccination Histories, Stratified by HBIG Without HBIG With HBIG HBsAgþ HBsAgþ Total n (%) aor* 95% CI Total N (%) aor* 95% CI HB vaccination during infancy and early childhood Dosage 4 doses 5, (1.0) (15.2) doses 1, (1.6) 1.52 ( ) (17.5) 1.21 ( ) 12 doses (2.9) 2.85 ( ) 4 0 (0.0) - Completion Yes 6, (1.1) (15.8) 1.00 No (1.8) 1.59 ( ) 28 3 (10.7) 0.64 ( ) On-schedule Yes 2, (1.0) (17.2) 1.00 No 4, (1.3) 1.30 ( ) (13.5) 0.76 ( ) *In addition to histories of HB vaccination, ORs were also adjusted for age and gender. Defined as HB vaccination administered before 3 years of age. Defined as those who received 3 doses of HB vaccination before 12 months of age. 0-7 days, 4-6 weeks, and 8-10 weeks after birth for the 1 st,2 nd, and 3 rd dose, respectively. aor, adjusted odds ratio; CI, confidence interval; HB, hepatitis B; HBIG, hepatitis B immunoglobulin; HBsAg, hepatitis B surface antigen; ND, no documentation. k test for trend, P ¼ 0.011; P < 0.05.
5 42 WU, LIN, AND WANG HEPATOLOGY, January 2013 Table 3. HBsAg-Positive Rates in 373 Adolescents Who Had Received Postnatal Passive-Active HB Vaccination HBsAgþ Total No. (%) P Date of HBIG dosing 0.60 Date of birth (14.6) The next date (19.4) After the next date 6 1 (16.7) Maternal HBeAg status 0.60 ND (14.7) Negative 27 3 (11.1)* Positive (17.8)* HBIG at date of birth (14.9) HBIG at the next date 31 9 (29.0) HBIG at the other dates 3 0 (0.0) *Exact one-sided P ¼ Exact one-sided P ¼ HBeAg, hepatitis B e antigen; HBIG, hepatitis B immune globulin; HBsAg, hepatitis B surface antigen; ND, no documentation. for subjects who received HBIG injection at the date of birth than that of the next date after delivery (14.6% versus 19.4%, one-sided P ¼ 0.14). Among 162 subjects with documented maternal HBeAg status, the HBsAg-positive rate was significantly higher for HBeAg seropositivity than that of seronegativity (17.8% versus 11.1%, one-sided P ¼ 0.014). Among 135 students with maternal HBeAg seropositivity, 101 and 31 of them received HBIG injection at the date of birth and the next day after delivery, respectively. The HBsAg-positive rate was significantly lower for those dosed at the date of birth than that of those receiving a dose on the next day (14.9% versus 29.0%, one-sided P ¼ 0.032). Among 4,364 HBsAg- and anti-hbs-negative students, 2,057 of them were recruited in the HB revaccination study. There was no significant difference in the HB vaccination histories between responders and nonresponders. Twenty-two participants were anti- HBc-positive and another 35 participants with prebooster anti-hbs titers 10 miu/ml were excluded. Additionally, 26 participants who failed to provide postbooster blood samples were further excluded, leaving a total of 1,974 participants in the revaccination study. The proportions of postbooster anti-hbs titers <10, 10-99, and 100 miu/ml were 27.9, 29.7 and 42.4%, respectively (Table 4). There was a significant association between pre- and postbooster anti-hbs titers (P < ). Among 1,252 booster recipients who had prebooster anti-hbs titers of <1.0 miu/ml, the postbooster anti-hbs titers <10, 10-99, and 100 miu/ml were 40.6, 31.6, and 27.8%, respectively. The corresponding figures in 722 booster recipients who had prebooster anti-hbs titers of miu/ml were 5.8, 26.6, and 67.6%, respectively. The anti-hbs seropositive rate before booster was 48.3% (PR 1 ) and the response rate in the booster recipients was 72% (PR 2 ). The overall anti-hbs seropositive rate after a booster dose of HB vaccine was estimated to be 84.3%. Discussion In the present study we found that the HBsAg seropositive rate in high-risk subjects who received HBIG injection 15 years ago was as high as 15%. The HBsAg seropositive rates were much higher in subjects with maternal HBeAg-positivity and received HBIG injection off-schedule. To the best of our knowledge, there is no research reporting the cumulative risk of 10 years or more of HBV chronic infection in subjects who received an HBIG injection in infancy. It has been suggested that mother-to-infant transmission was the primary route of HBV infection in Taiwan. 3 Approximately 90% of infants of HBeAgpositive mothers were persistently positive for HBsAg. 4,5 Although postnatal passive-active HB immunization was proven to be very efficacious, nonetheless persistent HBV infection in immunized subjects were observed in Taiwan and other countries Moreover, a prospective study enrolled 665 high-risk newborns who were immunized with HBIG within 24 hours after delivery and subsequently received 3 doses of HB vaccination. 19 Sixteen of the cohort members were positive for HBsAg within 1 hour after delivery and remained HBsAg-positive at 6 months of age. 19 This evidence indicated that immunoprophylaxis failure occurred in a few high-risk infants even though HBIG was administered immediately after delivery. In Taiwan, only high-risk infants whom were born to women with HBeAg positivity or high levels of HBsAg were eligible for HBIG injection. It is reasonable to Table 4. Relationship Between Pre- and Post-booster anti-hbs Titers Postbooster anti-hbs levels (miu/ml) Prebooster anti-hbs levels (miu/ml) n < ,000 All 1, < <1.0 1,
6 HEPATOLOGY, Vol. 57, No. 1, 2013 WU, LIN, AND WANG 43 hypothesize that the observed high HBsAg seropositive rate in HBIG recipients in the present study was associated with high maternal HBV infectiousness. It was recommended that passive-active HB vaccination should be administered as soon as possible after birth. 1 In the present study, around 25% of all HBIG recipients and 22% of HBeAg positive recipients did not received HBIG at the date of birth. Statistically, those who did not receive HBIG injection at the date of delivery had a higher HBsAg seropositive rate. Consequently, off-schedule HBIG injection could possibly contribute to the observed significantly higher HBsAgpositive rate in the present study. HBV transmission during early childhood is another major determinant of countries with HBsAg hyperendemicity. 1 Herd immunity induced by mass or nationwide vaccination programs is well documented The HBsAg seropositive rates in newborns with maternal HBeAg-positivity and who had received passiveactive HB immunization were 4%-6% at the age of 1 year. 4,16,17 Among infants who were born to women with low or unknown levels of HBsAg, the HBsAgpositive rate at 15 months of age were 2.5% and 5.5% for subjects who had received HB vaccines on- and off-schedule, respectively. 16 A more recent population study of passive-active HB-immunized infants reported that 15 (4.2%) of 357 subjects with maternal HBeAgpositivity were HBsAg-positive at 2 years of age. 18 Among infants who were born by HBeAg-negative carriers and noncarriers, the corresponding figures were 0.8% and 0.2%, respectively. 18 This evidence suggested that an HB vaccination program significantly decreased the risk of HBV infection during infancy and early childhood in the low- and high-risk populations in Taiwan. All subjects in the present study were born after the implementation of UIHBVP, therefore, the attributable risk for HBV infection during infancy and early childhood in HBsAg chronic infection should not be too high. HBV reactivation or infection in later life, especially in those who have low or no immunological memories against HBsAg, is the major determinant of HBV chronic infection in low HBsAg endemic countries 1 and should be taken into consideration. HBV reactivation in transplant recipients is well documented A long-term prospective study of HB vaccination and risk of HBV infection in infants born to HBeAgpositive mothers showed that the natural infection rate of HBV before 3 years of age was 12%. 17 Additionally, during the 5-year follow-up period, none of the anti- HBc-positive infants became HBsAg-positive. 17 In another prospective study of 805 infants who were uninfected and anti-hbs-positive by 1 year of age, 52 of them became HBV-infected at the age of 1 to 5 years. An additional 61 subjects became HBV-infected at the age of 5 to 10 years. The cumulative 10-year risk of HBV infection was 15%. 24 Additionally, among 113 HBV-infected subjects, four became chronically infected. 24 In a more recent study, the anti-hbc and HBsAg-positive rates were 12% and 0%, respectively, in children aged 5 to 10 years. 25 This evidence indicated that even in high-risk children the cumulative 10-year risk of HBV reactivation or infection is moderate and the risk of becoming an HBV carrier is low. These findings were supported by the evidence that the protective effects of HB vaccination can last for at least 10 years. 27,28 However, whether protective effects of HB vaccination can persist for much longer in high-risk subjects as well as the risk of becoming an HBV carrier in subjects who contracted HBV infection after 10 years of age are both far from being investigation. In the present study, the overall anti-hbs seropositive rate after a booster dose of HB vaccine was estimated to be 84.3%. It was suggested that an anti-hbs titer of 10 miu/ml is necessary for the prevention of HBV infection. 38 Therefore, about one-sixth of subjects who had received infantile HB vaccination may have no or low immunological memories against HBsAg at 15 years of age and subsequently had elevated risk of HBV chronic infection when exposed to HBV. A recent study assayed the HBV markers in a cohort of 78 adolescents with maternal HBeAg positivity who had developed protective levels of anti-hbs during infancy. The anti-hbc-positive rate of the cohort member was 33.3% at 15 years of age. 26 One child became HBsAg-positive at the age 7 to 15 years old. 26 On the other hand, the cumulative risks of HBV infection in high-risk subjects younger than 10 years of age were less than 15%. 24,25 However, whether the risks of HBV infection or reactivation in high-risk subjects increase significantly at 10 years or more after infantile HB vaccination needs further investigation. In the present work, we found that a significant proportion of adolescents who were born to high-risk mothers and received postnatal passive-active HB immunization were HBsAg-positive. It seems that HBV infection or reactivation in adolescents with low or no immunological memories against HBsAg and motherto-infant HBV transmission were the primary determinants. HBsAg chronic carriers were at significantly higher risks of endstage liver diseases. 39,40 Our findings indicate that more efforts should be devoted to further reduce HBV transmission. Booster HB vaccination in
7 44 WU, LIN, AND WANG HEPATOLOGY, January 2013 subjects aged 15 years or more should be considered, especially in subjects born to HBsAg-positive mothers or who had a high risk of HBV exposure. Additionally, it is now routine practice to use antiretroviral therapy in pregnant women with human immunodeficiency virus infection to prevent mother-to-infant transmission. 41,42 Preliminary studies have shown that lamivudine 43,44 and telbivudine 45 during pregnancy may reduce vertical transmission of HBV. The routine use of anti-hbv treatment during pregnancy for those with high viral load awaits further study to confirm efficacy and safety. There were concerns that needed to be addressed. Undetermined accuracy of the HB vaccination histories could result in information bias. Before the implementation of the National Health Insurance Program in March 1995 in Taiwan, the main provider of primary healthcare was the local health station. Hualien County is an area with limited healthcare resources. It was reasonable to hypothesize that most of the infants received vaccination in nearby local health stations and their vaccination data were recorded immediately in the yellow log-sheet by well-trained health professionals. Our estimates were comparable to previous research. The population-based study, which selected a random sample of 1,500 children born September 1986 to August 1987 from the whole Taiwan area, found that 87.2% received 3 doses of HB vaccination. 46 In the present study, 4.8% of study subjects had documentation of HBIG injection, which is also similar to previous research. 14,18 More important, among subjects who had vaccination data from two different sources, the consistency in dates of HB vaccination was as high as 94.5%. We abstracted records of HB revaccination without knowing the subjects HBsAg serostatus. Consequently, information bias should be minimal and nondifferential in the present study. Additionally, less than half of the HBsAg- and anti- HBs-negative students were recruited in the HB revaccination study and less than 45% of the HBIG recipients had known maternal HBeAg status. We found that there was no significant difference in the HB vaccination histories between responders and nonresponders of the HB revaccination study (HB vaccination 3 dosages: 82.8% versus 84.4%; complete rate: 75.3% versus 77.3%) and between HBIG recipients with known and unknown maternal HBeAg status (HB vaccination 3 dosages: 97.5% versus 98.1%; complete rate: 89.8% versus 90.7%). It is therefore believed that bias associated with nonresponse was minimal in the HB revaccination study. In conclusion, having a high-risk mother is one of the most important determinants for HBsAg positivity at adolescence. A significant proportion of adolescents who had received primary infantile HB vaccination may have lost their immunological memories against HBsAg. Routine use of anti-hbv treatment during pregnancy might be an option, if safety and efficacy are proven by further large-scale studies. Booster HB vaccination in subjects aged 15 years or more should be considered, especially in subjects born to HBsAgpositive mothers or who have a high risk of HBV exposure. Acknowledgment: We thank the staffs of the health stations in Hualien County and the Center of Disease Control, Department of Health, Taiwan, for valuable contributions. References 1. World Health Organization (WHO). Hepatitis B vaccine. WHO Weekly Epidemiological Record 2009;84: Sung JL, Chen DS, Lai MY, Yu JY, Wang TH, Wang CY, et al. Epidemiological study on hepatitis B virus infection in Taiwan. Chin J Gastroenterol 1984;1: Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975;292: Beasley RP, Hwang LY, Lee GC, Lan CC, Roan CH, Huang FY, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983;2: Lo KJ, Tsai YT, Lee SD, Wu TC, Wang JY, Chen GH, et al. Immunoprophylaxis of infection with hepatitis B virus in infants born to hepatitis B surface antigen-positive carrier mothers. J Infect Dis 1985;152: Wong VC, Ip HM, Reesink HW, Lelie PN, Reerink-Brongers EE, Yeung CY, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-b vaccine and hepatitis-b immunoglobulin. Doubleblind randomised placebo-controlled study. Lancet 1984;1: Chen DS, Hsu NH, Sung JL, Hsu TC, Hsu ST, Kuo YT, et al A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA 1987;257: Whittle HC, Inskip H, Hall AJ, Mendy M, Downes R, Hoare S. Vaccination against hepatitis B and protection against chronic viral carriage in The Gambia. Lancet 1991;337: Da Villa G, Picciottoc L, Elia S, Peluso F, Montanaro F, Maisto T. Hepatitis B vaccination: universal vaccination of newborn babies and children at 12 years of age versus high risk groups. A comparison in the field. Vaccine 1995;13: Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan. JAMA 1996;276: Lin HH, Lin SS, Chiang YM, Wang LY, Huang LC, Huang SC, et al. Trend of hepatitis B virus infection in freshmen classes at two high schools in Hualien, Taiwan from 1991 to J Med Virol 2002;67: Wang LY, Hu CT, Ho TY, Lin HH. Geographic and ethnic variations of long-term efficacy and immunogenicity of hepatitis B vaccination in Hualien, a HBV hyperendemic area. Vaccine 2006;24: Chen HL, Chang CJ, Kong MS, Huang FC, Lee HC, Lin CC, et al. Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination. HEPATOLOGY 2004;39:58-63.
8 HEPATOLOGY, Vol. 57, No. 1, 2013 WU, LIN, AND WANG Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997;336: Lee CL, Hsieh KS, Ko YC. Trends in the incidence of hepatocellular carcinoma in boys and girls in Taiwan after large-scale hepatitis B vaccination. Cancer Epidemiol Biomarkers Prev 2003;12: Hsu HM, Chen DS, Chuang CH, Lu JC, Jwo DM, Lee CC, et al. Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3464 infants of hepatitis B surface antigen-carrier mothers. JAMA 1988;260: Lee PI, Lee CY, Huang LM, Chang MH. Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen. J Pediatr 1995;126: Hsu HM, Lee SC, Wang MC, Lin SF, Chen DS. Efficacy of a mass hepatitis B immunization program after switching to recombinant hepatitis B vaccine: a population-based study in Taiwan. Vaccine 2001;19: Tang JR, Hsu HY, Lin HH, Ni YH, Chang MH. Hepatitis B surface antigenemia at birth: a long-term follow-up study. J Pediatr 1998;133: Grosheide PM, del Canho R, Heijtink RA, Nuijten AS, Zwijnenberg J, Banffer JR, et al. Passive-active immunization in infants of hepatitis Be antigen-positive mothers. Comparison of the efficacy of early and delayed active immunization. Am J Dis Child 1993;147: Noto H, Terao T, Ryou S, Hirose Y, Yoshida T, Ookubo H, et al. Combined passive and active immunoprophylaxis for preventing perinatal transmission of the hepatitis B virus carrier state in Shizuoka, Japan during J Gastroenterol Hepatol 2003;18: Wang Z, Zhang J, Yang H, Li X, Wen S, Guo Y, et al. Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies. J Med Virol 2003;71: Shao ZJ, Zhang L, Xu JQ, Xu DZ, Men K, Zhang JX, et al. Motherto-infant transmission of hepatitis B virus: a Chinese experience. J Med Virol 2011;83: Wu JS, Hwang LY, Goodman KJ, Beasley RP. Hepatitis B vaccination in high-risk infants: 10-year follow-up. Infect Dis 1999;179: Huang LM, Chiang BL, Lee CY, Lee PI, Chi WK, Chang MH. Longterm response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. HEPATOLOGY 1999;29: Lu CY, Chiang BL, Chi WK, Chang MH, Ni YH, Hsu HM, et al. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. HEPATOLOGY 2004;40: Zanetti AR, Mariano A, Roman L, D Amelio R, Chironna M, Coppola RC, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005;366: McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, Nainan O, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005;142: Ministry of Interior. Statistical Yearbook of Interior. Republic of China: Ministry of Interior, Executive Yuan; Available at: moi.gov.tw/micst/stmain.jsp?sys¼100. Accessed 20 April Wang LY, Lin HH. Ethnicity, substance use, and response to booster hepatitis B vaccination in anti-hbs-seronegative adolescents who had received primary infantile vaccination. J Hepatol 2007;46: Wang LY, Lin HH. Short-term response to a booster dose of hepatitis B vaccine in anti-hbs negative adolescents who had received primary vaccination 16 years ago. Vaccine 2007;25: Garland SM, Skinner SR, Brotherton JM. Adolescent and young adult HPV vaccination in Australia: achievements and challenges. Prev Med 2011;53 S1:S29-S Kim TH, Johnstone J, Loeb M. Vaccine herd effect. Scand J Infect Dis 2011;43: Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009;8: Nery JR, Nery-Avila C, Reddy KR, Cirocco R, Weppler D, Levi DM, et al. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-hbc) in the era of prophylaxis with hepatitis-b immunoglobulin and lamivudine. Transplantation 2003;75: Jain A, Orloff M, Abt P, Kashyap R, Mohanka R, Lansing K, et al. Use of hepatitis B core antibody-positive liver allograft in hepatitis C virus-positive and -negative recipients with use of short course of hepatitis B immunoglobulin and lamivudine. Transplant Proc 2005;37: Roche B, Roque-Afonso AM, Sebagh M, Delvart V, Duclos-Vallee JC, Castaing D, et al. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins. Liver Transpl 2010;16: Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective? J Infect Dis 1999;179: Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347: Chen CJ, Yang HI, Iloeje UH; >REVEAL-HBV Study Group. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. HEPATOLOGY 2009;49(Suppl):S72-S Read JS. Prevention of mother-to-child transmission of HIV: antiretroviral strategies. Clin Perinatol 2010;37: Becquet R, Ekouevi DK, Arrive E, Stringer JS, Meda N, Chaix ML, et al. Universal antiretroviral therapy for pregnant and breast-feeding HIV-1-infected women: towards the elimination of mother-to-child transmission of HIV-1 in resource-limited settings. Clin Infect Dis 2009;49: van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003;10: Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebocontrolled study. J Viral Hepat 2009;16: Han GR, Cao MK, Zhao W, Jiang HX, Wang CM, Bai SF, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011;55: Hsu HM, Lu CF, Lee SC, Lin SR, Chen DS. Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization. J Infect Dis. 1999;179:
Department of Public Health, Taipei Medical University, Taipei City, Taiwan
Page 1 of 30 1 TITLE PAGE Title: Chronic hepatitis B infection in adolescents who had received primary infantile vaccination. Authors and affiliations Tzu-Wei Wu 1,*, Hans Hsienhong Lin 2,3*, Li-Yu Wang
More informationHepatitis B virus (HBV) infection is an important. Brief Communication
Brief Communication Hepatitis B Virus Infection in Children and Adolescents in a Hyperendemic Area: 15 Years after Mass Hepatitis B Vaccination Yen-Hsuan Ni, MD, PhD; Mei-Hwei Chang, MD; Li-Min Huang,
More informationIncomplete Hepatitis B Immunization, Maternal Carrier Status, and Increased Risk of Liver Diseases: A 20-Year Cohort Study of 3.8 Million Vaccinees
Incomplete Hepatitis B Immunization, Maternal Carrier Status, and Increased Risk of Liver Diseases: A 20-Year Cohort Study of 3.8 Million Vaccinees Yin-Chu Chien, 1 Chyi-Feng Jan, 2 Chun-Ju Chiang, 3 Hsu-Sung
More informationEstimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants
ORIGINAL ARTICLE Estimation of Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Taiwan from a Large-scale Survey of Free Hepatitis Screening Participants Chien-Hung Chen, 1 Pei-Ming Yang, 1
More informationTwo Decades of Universal Hepatitis B Vaccination in Taiwan: Impact and Implication for Future Strategies
GASTROENTEROLOGY 2007;132:1287 1293 Two Decades of Universal Hepatitis B Vaccination in Taiwan: Impact and Implication for Future Strategies YEN HSUAN NI,* LI MIN HUANG,* MEI HWEI CHANG,* CHUNG JEN YEN,
More informationHepatitis B surface antigen HBsAg Hepatitis B e antigen HBeAg 1) B
292 14 4 B Effects of the Vaccination Against Hepatitis B Virus for All Infants in Taiwan Chang-Kuen Tien, Nobutaka Kurihara, Hiroyuki Yanagisawa and Osamu Wada (Hygiene and Preventive Medicine, Saitama
More informationUniversal hepatitis B (HB) immunization has
Determination of Immune Memory to Hepatitis B Vaccination Through Early Booster Response in College Students Chyi-Feng Jan, 1,2 Kuo-Chin Huang, 1 Yin-Chu Chien, 3 Donald E. Greydanus, 2 H. Dele Davies,
More informationHEPATITIS B VACCINATION IN TAIWAN AND THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHILDREN
UNIVERSAL HEPATITIS B VACCINATION IN TAIWAN AND THE INCIDENCE OF HEPATOCELLULAR CARCINOMA IN CHILDREN MEI-HWEI CHANG, M.D., CHIEN-JEN CHEN, SC.D., MEI-SHU LAI, M.D., HSU-MEI HSU, M.P.H., TZEE-CHUNG WU,
More informationAlthough substantial progress has been made in
VIRAL HEPATITIS Waning Immunity to Plasma-Derived Hepatitis B Vaccine and the Need for Boosters 15 Years After Neonatal Vaccination Chun-Yi Lu, 1 Bor-Luen Chiang, 1,2 Wei-Kuang Chi, 3 Mei-Hwei Chang, 1
More informationHEPATITIS B: PREGNANCY AND LABOR MANAGEMENT MICHAEL P. NAGEOTTE, M.D.
HEPATITIS B: PREGNANCY AND LABOR MANAGEMENT MICHAEL P. NAGEOTTE, M.D. Disclosures I have no relevant financial relationships to disclose or conflicts of interest to resolve. I will not discuss any unapproved
More informationHumoral and Cellular Immune Responses to a Hepatitis B Vaccine Booster Years after Neonatal Immunization
MAJOR ARTICLE Humoral and Cellular Immune Responses to a Hepatitis B Vaccine Booster 15 18 Years after Neonatal Immunization Chun-Yi Lu, 1 Yen-Hsuan Ni, 1 Bor-Luen Chiang, 1 Pei-Jer Chen, 2 Mei-Hwei Chang,
More informationLong term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers
Archives of Disease in Childhood 1997;77:F47 F51 F47 Viral Hepatitis Research Unit Chulalongkorn University Hospital, Bangkok, Thailand Y Poovorawan Department of Paediatrics S Sanpavat S Chumdermpadetsuk
More informationEpatite B: fertilità, gravidanza ed allattamento, aspetti clinici e terapeutici. Ivana Maida
Epatite B: fertilità, gravidanza ed allattamento, aspetti clinici e terapeutici Ivana Maida Positivity for HBsAg was found in 0.5% of tested women In the 70s and 80s, Italy was one of the European countries
More informationHepatitis B virus (HBV) infection can cause
Prevention of Hepatitis B Mei-Hwei Chang 1,2 and Ding-Shinn Chen 2,3,4 1 Department of Pediatrics, National Taiwan University Hospital, Taipei 10016, Taiwan 2 Hepatitis Research Center, National Taiwan
More informationHepatitis B virus (HBV) is a significant cause of
Secular Trend of the Viral Genotype Distribution in Children With Chronic Hepatitis B Virus Infection After Universal Infant Immunization Wan-Hsin Wen, 1,6,7 Huey-Ling Chen, 1,2 Yen-Hsuan Ni, 1 Hong-Yuan
More informationKey words: HBV, Taiwan, epidemiology, vaccination program, hepatitis B vaccine
Original Article 521 Forecasting the Declining Rate of Chronic Hepatitis- Carrier Status at a Taiwanese University: Twenty Years after Implementation of an Universal HV Vaccination Program in Taiwan Fu-Hsiung
More informationuniversal vaccination
Vol. 21No. 2149 8 HB B universal vaccination Blumberg HBs B 40 B HBV HBV HBV HBs WHO 1992 HBV B HB universal vaccination 1997 HB universal vaccination HBV high risk HBV universal vaccination B HBV universal
More informationHepadnaviridae family (DNA) Numerous antigenic components Humans are only known host May retain infectivity for more than 7 days at room temperature
Hepatitis B Epidemic jaundice described by Hippocrates in 5th century BC Jaundice reported among recipients of human serum and yellow fever vaccines in 1930s and 1940s Australia antigen described in 1965
More informationHepatitis B vaccine alone or with HBIG in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis.
Hepatitis B vaccine alone or with HBIG in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis. Vana Papaevangelou (Greece) National and Kapodistrian University of Athens Chang SemFNM
More informationSummary of Seroprotection after Recombinant Hepatitis B Vaccine Administered to Newborn Infants (defined as the first 30 days of Life) Background:
Prepared by: TV Murphy, MD, September 16, 2016 Summary of Seroprotection after Recombinant Hepatitis B Vaccine Administered to Newborn Infants (defined as the first 30 days of Life) Background: The primary
More informationHBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board
HBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board 2 nd Hepatitis Cure and Eradication Meeting 11 12 November 2015 Declaration of Interest
More informationThe Evolving Landscape of Preventing Maternal-Fetal Hepatitis B Infections
The Evolving Landscape of Preventing Maternal-Fetal Hepatitis B Infections Neil S. Silverman, M.D. Center for Fetal Medicine and Women s Ultrasound Clinical Professor, Obstetrics/Gynecology David Geffen
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More informationAN ECONOMIC EVALUATION OF UNIVERSAL INFANT VACCINATION STRATEGIES AGAINST HEPATITIS B IN THAILAND: AN ANALYTIC DECISION APPROACH TO COST-EFFECTIVENESS
AN ECONOMIC EVALUATION OF UNIVERSAL INFANT VACCINATION STRATEGIES AGAINST HEPATITIS B IN THAILAND: AN ANALYTIC DECISION APPROACH TO COST-EFFECTIVENESS Thosporn Vimolket 1 and Yong Poovorawan 2 1 Department
More informationS ince effective vaccines against hepatitis B became
1499 LIVER Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan H-Y Hsu, M-H Chang, Y-H Ni, H-L Chen... See end of article for authors
More informationThe Hepatitis B Vaccine: What Went Wrong?
The Hepatitis B Vaccine: What Went Wrong? By F. Edward Yazbak, MD, FAAP On Dec. 23, 2005, the Centers for Disease Control and Prevention (CDC) published a Morbidity and Mortality Weekly Report (1) in which
More informationHepatitis B and Hepatitis B Vaccine
Hepatitis B and Epidemiology and Prevention of Vaccine- Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at http://www.vaccineinformation.org/photos/index.asp
More informationClinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL
Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL The World Health Organisation recent initiatives on HBV infection Launching of the
More informationHBV-2 Group: neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (Part of
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAre booster immunisations needed for lifelong hepatitis B immunity?
Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B immunity, following meeting in Florence in October 1998 To date there are no data to support
More informationDecreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study
ARTICLE Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study Mei-Hwei Chang, San-Lin You, Chien-Jen Chen, Chun-Jen Liu, Chuan-Mo Lee, Shi-Ming Lin, Heng-Cheng
More informationHepatitis B Virus in Pregnancy
REVIEW REVIEW Hepatitis B Virus in Pregnancy Tram T. Tran, M.D. Chronic hepatitis B virus (HBV) infection remains an important worldwide cause of chronic liver disease, which may lead to the development
More informationMore than 2 billion people in the world are infected
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2004;2:941 945 18-Year Follow-up Study of a Prospective Randomized Trial of Hepatitis B Vaccinations Without Booster Doses in Children MAN FUNG YUEN,* WEI LING
More informationDownloaded from:
Whittle, H; Jaffar, S; Wansbrough, M; Mendy, M; Dumpis, U; Collinson, A; Hall, A (22) Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ, 325
More informationChapter 5 Serology Testing
Chapter 5 Serology Testing 49 50 This page intentionally left blank. Diagnostic Tests for Hepatitis B Virus (HBV) Diagnosis of HBV infection (acute vs. chronic) is based on clinical, laboratory, and epidemiologic
More informationObservational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children
Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children Hilton Whittle, Shabbar Jaffar, Michael Wansbrough, Maimuna Mendy, Uga Dumpis, Andrew Collinson,
More informationViral Hepatitis in Reproductive Health
Viral Hepatitis in Reproductive Health Training Course in Sexual and Reproductive Health Research Geneva 2010 Dr José M Bengoa Dr Pierre Jean Malè Consultants Division of Gastroenterology and Hepatology
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationChing-Wen Wang, Li-Chieh Wang, Mei-Hwei Chang,* Yen-Hsuan Ni, Huey-Ling Chen, Hong-Yuan Hsu, and Ding-Shin Chen
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Dec. 2005, p. 1442 1447 Vol. 12, No. 12 1071-412X/05/$08.00 0 doi:10.1128/cdli.12.12.1442 1447.2005 Copyright 2005, American Society for Microbiology. All
More informationEAST LONDON INTEGRATED CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationChronic hepatitis B in pregnancy: unique challenges and opportunities
The Korean Journal of Hepatology 2011;17:1-8 DOI: 10.3350/kjhep.2011.17.1.1 Review Chronic hepatitis B in pregnancy: unique challenges and opportunities Kumaresan Yogeswaran and Scott K. Fung Department
More informationSummary of Key Points. WHO Position Paper on Vaccines against Hepatitis B, July 2017
Summary of Key Points WHO Position Paper on Vaccines against Hepatitis B, July 2017 1 Background l HBV is transmitted by exposure of mucosal membranes or non-intact skin to infected blood, saliva, semen
More informationUniversal immunization beginning at birth and
AMERICAN ASSOCIATION FOR THE STUDY OFLIVERD I S E ASES HEPATOLOGY, VOL. 64, NO. 5, 2016 Quantitative Maternal Hepatitis B Surface Antigen Predicts Maternally Transmitted Hepatitis B Virus Infection Wan-Hsin
More informationMA PERINATAL HEPATITIS B PREVENTION PROGRAM
MA PERINATAL HEPATITIS B PREVENTION PROGRAM Massachusetts Department of Public Health Immunization Program MIAP 2016 1 1 Presenter Disclosure Information I, Theodora Wohler, have been asked to disclose
More informationB C ALT B C B B C
2006 17 276-290 520 ( Hepatitis surface antigen, HsAg ) ( Anti-hepatitis virus antibody anti-hv ) ( alanine transaminase ) 2004 4 11 31 533 216 (n=56702; / : 17551/39151) HsAg anti-hv 40 IU/L (standardized
More informationAUTHORS: Isnihaya M. Mapandi, MD Northern Mindanao Medical Center KEYWORDS Seroconversion, Hep B vertical transmission, Hepatitis B vaccine,
32 SEROLOGIC STATUS OF NEONATES BORN TO HEPATITIS B POSITIVE MOTHERS AND GIVEN HEPATITIS B VACCINE AT BIRTH IN A TERTIARY GOVERNMENT HOSPITAL FROM JANUARY 2007 TO JUNE 2008: A PILOT STUDY AUTHORS: Isnihaya
More informationHBsAg(+) mothers is a transient
Perinatal HBV viremia in newborns of HBsAg(+) mothers is a transient phenomenon that does not necessarily imply HBV infection transmission Vana Papaevangelou (Greece) National and Kapodistrian University
More informationCITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationPERINATAL HEPATIDES AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) Pamela Palasanthiran Staff Specialist, Paediatric Infectious Diseases
PERINATAL HEPATIDES AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) Pamela Palasanthiran Staff Specialist, Paediatric Infectious Diseases Viruses in July (ViJ), 2004 Overview Epidemiology Perinatal transmission
More informationHEPATITIS B: are escape mutants of concern?
VACCINATION: AN EVOLUTIONARY ENGINE FOR SPECIES? Fondation Mérieux Conference Centre Veyrier-du-Lac, France November 25-27, 2013 HEPATITIS B: are escape mutants of concern? Alessandro ZANETTI Department
More informationHEPATITIS B ELIMINATION IN ALASKA Lisa Townshend-Bulson, RN, MSN, FNP-C Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium
HEPATITIS B ELIMINATION IN ALASKA Lisa Townshend-Bulson, RN, MSN, FNP-C Liver Disease and Hepatitis Program Alaska Native Tribal Health Consortium Anchorage, Alaska USA Goals of My Lecture Highlight the
More informationCURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated
More informationHepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY November 2011
Viral Hepatitis Prevention Board Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY 17-18 November 2011 Objectives To review long-term efficacy of hepatitis B vaccine
More informationEvidence of protection against clinical and chronic hepatitis B infection 20 year after infant vaccination in Thailand
Evidence of protection against clinical and chronic hepatitis B infection 20 year after infant vaccination in Thailand http://waipra.blogspot.com/2011/02/9.html Burden of disease in Thailand Liver diseases
More informationRole of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation
BRIEF REPORT Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation Man-Fung Yuen, 1 Erwin Sablon, 2 Danny Ka-Ho Wong, 1 He-Jun Yuan, 1 Benjamin Chun-Yu Wong, 1 Annie On-On Chan, 1 and
More informationHepatitis B (Hep-B) is one of the most
Paediatrica Indonesiana VOLUME 50 November NUMBER 6 Original Article Influence of Hepatitis B immunization to prevent vertical transmission of Hep-B virus in infants born from Hep-B positive mother Liza
More informationHepatitis B Disease Burden: A Model for Global Estimates and Impact of Vaccination. Susan A. Wang, MD, MPH Division of Viral Hepatitis
Hepatitis B Disease Burden: A Model for Global Estimates and Impact of Vaccination Susan A. Wang, MD, MPH Division of Viral Hepatitis Barriers to Appreciating HBV Disease Burden and Vaccine Impact Chronic
More informationThe Hep B Moms Program: A Primary Care Model for Management of Hepatitis B in Pregnancy
The Hep B Moms Program: A Primary Care Model for Management of Hepatitis B in Pregnancy Janice Lyu, MS Senior Hepatitis B Program Associate Charles B. Wang Community Health Center (CBWCHC) Charles B Wang
More informationChapter 2 Hepatitis B Overview
Chapter 2 Hepatitis B Overview 23 24 This page intentionally left blank. HEPATITIS B OVERVIEW Hepatitis B Virus The hepatitis B virus (HBV) belongs to the Hepadnaviridae family and is known to cause both
More informationEpidemiology of hepatitis E infection in Hong Kong
RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES Epidemiology of hepatitis E infection in Hong Kong DPC Chan *, KCK Lee, SS Lee K e y M e s s a g e s 1. The overall anti hepatitis E virus (HEV) seropositivity
More informationHepatitis B virus (HBV) infection is a global
VIRAL HEPATITIS Serum Hepatitis B Surface Antigen Levels Help Predict Disease Progression in Patients With Low Hepatitis B Virus Loads Tai-Chung Tseng, 1,3,8 Chun-Jen Liu, 2,3 Hung-Chih Yang, 2,6 Tung-Hung
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis
More informationTreatment of hepatitis B : the guidelines and real life
Treatment of hepatitis B : the guidelines and real life Prince of Songkla University, Thailand Teerha Piratvisuth MD. NKC Institute of Gastroenterology and Hepatology Disclosure Statement of Financial
More informationA study on hepatitis-b in pregnant women and their neonatal outcome
International Journal of Medical and Health Research ISSN: 2454-9142, Impact Factor: RJIF 5.54 www.medicalsciencejournal.com Volume 3; Issue 2; February 2017; Page No. 126-130 A study on hepatitis-b in
More informationORIGINAL ARTICLE Hepatitis B seroepidemiology and booster vaccination in pre-clinical medical students in a Malaysian university
Malaysian J Pathol 2018; 40(3) : 295 302 ORIGINAL ARTICLE Hepatitis B seroepidemiology and booster vaccination in pre-clinical medical students in a Malaysian university Siti Norlia OTHMAN, Zetti ZAINOL
More informationSTATE TDAP VACCINE PROGRAM
STATE TDAP VACCINE PROGRAM CDPH provides free Tdap vaccine for local public health departments. This vaccine then is distributed to clinics through out county. Vaccine to be specifically given to: Woman
More informationEVALUATION OF THE SCHOOL-BASED HEPATITIS B VACCINATION PROGRAMME IN CATALONIA (SPAIN)
EVALUATION OF THE SCHOOL-BASED HEPATITIS B VACCINATION PROGRAMME IN CATALONIA (SPAIN) Prof. L. Salleras Department of Public Health University of Barcelona Hospital Clínic Barcelona Hepatitis B vaccine:
More informationBreastfeeding Is Not a Risk Factor for Mother-to-Child Transmission of Hepatitis B Virus
Breastfeeding Is Not a Risk Factor for Mother-to-Child Transmission of Hepatitis B Virus Xiangru Chen 1., Jie Chen 2., Jian Wen 3, Chenyu Xu 3, Shu Zhang 2, Yi-Hua Zhou 4,5 *, Yali Hu 2,5 * 1 Faculty of
More informationOB Provider Guide to Alaska s Perinatal Hepatitis B Prevention Program
OB Provider Guide to Alaska s Perinatal Hepatitis B Prevention Program Dear Colleague, This letter is to introduce myself and explain the role I play with the Alaska Perinatal Hepatitis B Program. Alaska
More informationElimination of Perinatal Hepatitis B Transmission
Elimination of Perinatal Hepatitis B Transmission Trudy V. Murphy, MD Division of Viral Hepatitis NCHHSTP, CDC December 19, 2013 Hep B United and WHIAAPI Webinar Background q Hepatitis B is an infection
More informationNatural History of HBV Infection
Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2
More informationHepatitis and pregnancy
Hepatitis and pregnancy Pierre-Jean Malè MD Training Course in Reproductive Health Research WHO Geneva 2008 26.02.2008 Liver disease and pregnancy: three possible etiologic relationship the patient has
More informationHepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016
Hepatitis B: A Preventable Cause of Liver Cancer Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Overview Epidemiology HBV and cancer Screening, Diagnosis
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More information24. Screening for Hepatitis B Virus Infection
Part D. Infectious Diseases 24. Screening for Hepatitis B Virus Infection RECOMMENDATION Screening with hepatitis B surface antigen (HBsAg) to detect active (acute or chronic) hepatitis B virus (HBV) infection
More informationAge-Period-Cohort Analysis of Hepatocellular Carcinoma Mortality in Taiwan,
Age-Period-Cohort Analysis of Hepatocellular Carcinoma Mortality in Taiwan, 1976 2005 LONG-TENG LEE, HSIAO-YUAN HUANG, KUO-CHIN HUANG, CHING-YU CHEN, AND WEN-CHUNG LEE PURPOSE: Hepatocellular carcinoma
More informationLong-term Antibody Response and Immunologic Memory in Children Immunized with Hepatitis B Vaccine at Birth
endocrine profile and factors indicating neurogenic precocity in Indian children. J Pediatr Endocrinol Metab 2002; 15: 1173-1181. 18. Avila NA, Shawker TS, Jones JV, Cutler GB Jr, Merke DP. Testicular
More informationHEPATITIS B INFECTION and Pregnancy. Caesar Mensah Communicable Diseases & Infection Control Specialist, UK June 2011
HEPATITIS B INFECTION and Pregnancy Caesar Mensah Communicable Diseases & Infection Control Specialist, UK June 2011 HEPATITIS B 26/07/2011 What is Hepatitis B? It is inflammation (infection) of the liver
More informationManagement of Hepatitis B - Information for primary care providers
Management of Hepatitis B - Information for primary care providers July 2018 Chronic hepatitis B (CHB) is often a lifelong condition. Not everyone infected needs anti-viral therapy. This document outlines
More informationLearning Objectives: Hepatitis Update. Primary Causes of Chronic Liver Disease in the U.S. Hepatitis Definition. Hepatitis Viruses.
Learning Objectives: Hepatitis Update ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Upon attendance of this seminar and review of material provided, the attendees will be able to: 1. List hepatitis viruses
More informationHepatitis B vaccine: long-term efficacy, booster policy, and impact of HBV mutants on hepatitis B vaccination programmes
Hepatitis B vaccine: long-term efficacy, booster policy, and impact of HBV mutants on hepatitis B vaccination programmes VHPB meeting, Seville, 11-12 March 2004 Immunization programmes Programmes protect
More informationShould we treat hepatitis B positive pregnant women to prevent mother to child transmission?
Should we treat hepatitis B positive pregnant women to prevent mother to child transmission? Daniel Shouval Liver Unit Hadassah-Hebrew University Hospital Jerusalem, Israel VHPB Vienna June 1-2, 2017 Background
More information9/12/2018. Hepatitis B Virus Infection. Hepatitis B Infection
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Hepatitis B and Hepatitis B Vaccine Adult Track Chapter 10 Photographs and images included in this presentation
More informationEpidemiology and Natural History of Hepatitis B in Children
Epidemiology and Natural History of Hepatitis B in Children Szu-Ta Chen and Mei-Hwei Chang Key Concepts Patients in countries with high HBV endemicity tend to have perinatal transmission of hepatitis B,
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationPerinatal Hepatitis b Prevention
Perinatal Hepatitis b Prevention Purpose 2 The primary goal of the Perinatal Hepatitis b Prevention Program (PHBPP) is to identify all pregnant women who are infected with hepatitis b and prevent perinatal
More informationNHS public health functions agreement Service specification No.1 Neonatal hepatitis B immunisation programme
NHS public health functions agreement 2017-18 Service specification No.1 Neonatal hepatitis B immunisation programme NHS public health functions agreement 2017-18 Service specification No.1Neonatal hepatitis
More informationMedia centre. WHO Hepatitis B. Key facts. 1 of :12 AM.
1 of 5 2013-08-02 7:12 AM Media centre Hepatitis B Share Print Fact sheet N 204 Updated July 2013 Key facts Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic
More informationUses and Misuses of Viral Hepatitis Testing. Origins of Liver Science
Uses and Misuses of Viral Hepatitis Testing Richard S Lang, MD, MPH, FACP Chairman, Preventive Medicine Vice-Chair, Wellness Institute Raul J Seballos, MD, FACP Vice-Chair, Preventive Medicine Wellness
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationSupplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a
Supplementary materials: Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis Yin-Chen Wang 1, Sien-Sing Yang 2*, Chien-Wei Su 1, Yuan-Jen Wang 3,
More informationPrevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy
Vaccine 24 (2006) 3095 3099 Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy Sudawan Siriaksorn a, Thanyawee
More informationUICC HPV and CERVICAL CANCER CURRICULUM. UICC HPV and Cervical Cancer Curriculum Chapter 5. Application of HPV vaccines Prof. Suzanne Garland MD
UICC HPV and CERVICAL CANCER CURRICULUM 01 Chapter 5. Application of HPV vaccines Director of Microbiological Research Director of Clinical Microbiology and Infectious Diseases The Royal Women's Hospital
More informationTB/HIV/STD Epidemiology and Surveillance Branch. First Annual Report, Dated 12/31/2009
TB/HIV/STD Epidemiology and Surveillance Branch First Annual Report, Dated 12/31/29 This Enhanced Perinatal Surveillance Report is the first annual report generated by the Texas Department of State Health
More informationSeroprotection after Hepatitis B Vaccination among Newborn Infants: a Review
Center for Global Health Seroprotection after Hepatitis B Vaccination among Newborn Infants: a Review Rania Tohme, MD, MPH Team Lead Global Immunization Division, US CDC Viral Hepatitis Prevention Board
More informationJournal Club 3/4/2011
Journal Club 3/4/2011 Maternal HIV Infection and Antibody Responses Against Vaccine-Preventable Diseases in Uninfected Infants JAMA. 2011 Feb 9;305(6):576-84. Jones et al Dept of Pediatrics, Imperial College,
More informationHepatitis B Postexposure Prophylaxis in Preterm and Low-Birth-Weight Infants
THIEME Case Report e67 Hepatitis B Postexposure Prophylaxis in Preterm and Low-Birth-Weight Infants Markus Waitz, MD 1 Reinhard Hopfner, MD 1 Helmut D. Hummler, MD 1 U. Heininger, MD 2 1 Division of Neonatology
More informationin pregnancy Document Review History Version Review Date Reviewed By Approved By
GYNAECOLOGY/ ANTENATAL CARE WIRRAL WOMEN & CHILDREN S HOSPITAL Guideline No: Hepatitis B management in pregnancy VERSION 1 AMENDMENTS MADE: N/A DATE OF ISSUE: May 2012 DATE OF REVIEW: May 2015 REVIEW INTERVAL:
More informationNHS public health functions agreement
NHS public health functions agreement 2016-17 Service specification No.1 Neonatal hepatitis B immunisation programme Classification: official NHS England INFORMATION READER BOX Directorate Medical Commissioning
More informationPerinatal Hepatitis B Prevention Program. Purpose
Perinatal Hepatitis B Prevention Program Presented by: Carolyn Perry, RN, BSN Purpose 2 The primary goal of the Perinatal Hepatitis B Prevention Program (PHBPP) is to identify all pregnant women who are
More information